title: [Impact of CACNA1C polymorphisms on antihypertensive efficacy of calcium channel blocker].
abstract: OBJECTIVE
  To explore the relationship between genetic polymorphisms of CACNA1C that encoded the a1c subunit of the L-type calcium channel and the efficacy of calcium channel blocker (CCB, Nifedipine extended release tablet/20 mg/d) in essential hypertension (EH) patients of Han Chinese in Wenzhou.
  
  
  METHODS
  For the enrolled 103 EH patients, Multiplex Polymerase Chain Reaction (Multi-PCR) and matrix assisted laser desorption ionization time of flight MS (MLDI-TOF MS) were performed to detect their genotypes (rs216008, rs1051375, rs2299661, rs10848683, rs215976), blood pressure (BP) after CCB monotherapy was compared among patients with different genotypes.
  
  
  RESULTS
  (1) Blood pressure was significantly reduced in all patients post CCB (P < 0.05 vs. pre-CCB). (2) Diastolic blood pressure reduction was more significant in subjects with rs2299661 C/C genotype (wild genotype) than in subjects with rs2299661C/G and rs2299661G/G genotype (mutational genotype) [(12.46 ± 7.91) mm Hg (1 mm Hg = 0.133 kPa) vs. (7.22 ± 8.01) mm Hg and (5.93 ± 9.77) mm Hg, P < 0.05]. (3) Systolic blood pressure reduction was more significant in subjects with rs216008 C/C genotype (wild genotype) than in subjects with rs216008 C/T genotype (mutational genotype) [(20.60 ± 12.35) mm Hg vs. (13.62 ± 10.21) mm Hg, P < 0.05]. (4) Blood pressure reduction was similar between subjects with genotype of rs1051375, rs10848683 and rs215976.
  
  
  CONCLUSIONS
  EH patients with wild genotype of rs2299661 and rs216008 in CACNA1C are more likely to be responders of CCB monotherapy.
authors.affiliation: Department of Clinical Laboratory, Wenzhou Medical College, Wenzhou, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Sun
authors.forename: Qing-xian
authors.initials: QX
authors.lastname: Li
authors.forename: Xi-fa
authors.initials: XF
authors.lastname: Song
authors.forename: Song-gui
authors.initials: SG
authors.lastname: Zheng
authors.forename: Feng
authors.initials: F
authors.lastname: Yan
authors.forename: Peng
authors.initials: P
authors.lastname: Chen
authors.forename: Ji-fei
authors.initials: JF
authors.lastname: Tang
authors.forename: Yu-xin
authors.initials: YX
authors.lastname: Niu
authors.forename: Qi-yu
authors.initials: QY
authors.lastname: Bao
authors.forename: Guo-qiang
authors.initials: GQ
authors.lastname: Zhang
authors.forename: Yun-liang
authors.initials: YL
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D020746:Calcium Channels, L-Type / Q000235:genetics*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide
chemical_list: C079146:CACNA1C protein, human; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type